Abstract
A large number of indolyl-4-azaindolyl thiazoles, nortopsentin analogues, were conveniently synthesized. The antiproliferative activity of the new derivatives was examined against four human tumor cell lines with different histologic origin. Seven derivatives consistently reduced the growth of the experimental models independently of TP53 gene status and exhibited the highest activity against the malignant peritoneal mesothelioma (STO) cell line. The most active compound of this series acts as a CDK1 inhibitor, and was found to cause cell cycle arrest at G2/M phase, to induce apoptosis by preventing the phosphorylation of survivin in Thr34 and to increase the cytotoxic activity of paclitaxel in STO cells.
Keywords: Antiproliferative activity, CDK1 inhibitors, diffuse malignant peritoneal mesothelioma, indolyl-4-azaindolyl thiazoles, nortopsentin analogues, survivin.
Current Medicinal Chemistry
Title:Synthesis and Antiproliferative Activity of Substituted 3[2-(1H-indol-3-yl)- 1,3-thiazol-4-yl]-1H-pyrrolo[3,2-b]pyridines, Marine Alkaloid Nortopsentin Analogues
Volume: 21 Issue: 14
Author(s): A. Carbone, M. Pennati, P. Barraja, A. Montalbano, B. Parrino, V. Spano, A. Lopergolo, S. Sbarra, V. Doldi, N. Zaffaroni, G. Cirrincione and P. Diana
Affiliation:
Keywords: Antiproliferative activity, CDK1 inhibitors, diffuse malignant peritoneal mesothelioma, indolyl-4-azaindolyl thiazoles, nortopsentin analogues, survivin.
Abstract: A large number of indolyl-4-azaindolyl thiazoles, nortopsentin analogues, were conveniently synthesized. The antiproliferative activity of the new derivatives was examined against four human tumor cell lines with different histologic origin. Seven derivatives consistently reduced the growth of the experimental models independently of TP53 gene status and exhibited the highest activity against the malignant peritoneal mesothelioma (STO) cell line. The most active compound of this series acts as a CDK1 inhibitor, and was found to cause cell cycle arrest at G2/M phase, to induce apoptosis by preventing the phosphorylation of survivin in Thr34 and to increase the cytotoxic activity of paclitaxel in STO cells.
Export Options
About this article
Cite this article as:
Carbone A., Pennati M., Barraja P., Montalbano A., Parrino B., Spano V., Lopergolo A., Sbarra S., Doldi V., Zaffaroni N., Cirrincione G. and Diana P., Synthesis and Antiproliferative Activity of Substituted 3[2-(1H-indol-3-yl)- 1,3-thiazol-4-yl]-1H-pyrrolo[3,2-b]pyridines, Marine Alkaloid Nortopsentin Analogues, Current Medicinal Chemistry 2014; 21 (14) . https://dx.doi.org/10.2174/09298673113206660307
DOI https://dx.doi.org/10.2174/09298673113206660307 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Tumor-Targeting Peptides: Ligands for Molecular Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Current Drug Safety Cancer Stem Cells Switch on Tumor Neovascularization
Current Molecular Medicine Angiogenesis and Angiogenic Inhibitors in Non Small Cell Lung Cancer
Current Angiogenesis (Discontinued) Multi-modal Anti-cancer Activities Provided by a Non-replicating Sendai Virus Envelope
Current Cancer Therapy Reviews Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer
Current Topics in Medicinal Chemistry Multidrug Transporters as Drug Targets
Current Drug Targets Targeting CREB for Cancer Therapy: Friend or Foe
Current Cancer Drug Targets Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Nanocarriers Based Anticancer Drugs: Current Scenario and Future Perceptions
Current Drug Targets Development of NGR-Based Anti-Cancer Agents for Targeted Therapeutics and Imaging
Anti-Cancer Agents in Medicinal Chemistry Disruption of Metabolic Pathways - Perspectives for the Treatment of Cancer
Current Cancer Drug Targets Progress of HDAC Inhibitor Panobinostat in the Treatment of Cancer
Current Drug Targets Editorial [Hot Topic: The Therapeutic Potential of Ribonucleases (Guest Editor: Urich Arnold) ]
Current Pharmaceutical Biotechnology Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia
Current Nanoscience Impaired Expression and Function of Signaling Pathway Enzymes by Anthocyanins: Role on Cancer Prevention and Progression
Current Enzyme Inhibition Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Mesothelioma - Update on Management
Current Respiratory Medicine Reviews